Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06686134Recruiting

Comprehensive Clinical Evaluation Study of GLP-1RA

Role: lead

NCT06140082Unknown

Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression

Role: lead

NCT06044558Completed

Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

Role: lead

NCT04932954Unknown

Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study

Role: lead

All 4 trials loaded